Table 6 The interaction between gene promoter region methylation and different cancer stages for 5-year OS of CRC patients.

From: Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan

 

Normal tissues

Tumor tissues

No. of subjects

No. of cases (%)

Crude

Adjusted

No. of subjects

No. of cases (%)

Crude

Adjusted

HR

95% CI

HR

95% CI

HR

95% CI

HR

95% CI

≧2 of genes

UnMe/local (1&2)

36

6 (16.7)

1.00

Referent

1.00

Referent

20

4 (20.0)

1.00

Referent

1.00

Referent

UnMe/advanced (3&4)

31

8 (25.8)

1.73

(0.60 to 5.00)

4.69

(0.98 to 22.5)

8

2 (25.0)

1.06

(0.20 to 5.81)

4.74

(0.42 to 53.2)

Me/local (1&2)

41

7 (17.1)

1.15

(0.39 to 3.41)

1.23

(0.22 to 6.91)

57

9 (15.8)

0.82

(0.25 to 2.66)

1.23

(0.14 to 10.9)

Me/advanced (3&4)

45

10 (22.2)

1.74

(0.63 to 4.79)

3.97

(0.83 to 19.1)

68

16 (23.5)

1.46

(0.49 to 4.38)

4.42

(0.57 to 34.5)

p for trend

  

0.44

 

0.31

   

0.40

 

0.10

 
  1. Abbreviations: OS, overall survival; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval.
  2. Adjusted for gender, age at surgery (continuous), adjuvant chemotherapy, histological grade and tumor ___location.
  3. UnMe/loccal (1&2): DNA promoter region unmethylated with cancer stage 1 or 2.
  4. UnMe/advanced (3&4): DNA promoter region unmethylated with cancer stage 3 or 4.
  5. Me/local (1&2): DNA promoter region methylated with cancer stage 1 or 2.
  6. Me/advanced (3&4): DNA promoter region methylated with cancer stage 3 or 4.
Back to article page